{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["NLRP3 inflammasome", "anti-seizure", "antiinflammation", "hippocampus", "kainic acid", "neferine", "neuroprotection"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35456948", "DateCompleted": {"Year": "2022", "Month": "04", "Day": "26"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "04", "Day": "08"}], "Language": ["eng"], "ELocationID": ["4130", "10.3390/ijms23084130"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "23", "Issue": "8", "PubDate": {"Year": "2022", "Month": "Apr", "Day": "08"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Neferine, an Alkaloid from Lotus Seed Embryos, Exerts Antiseizure and Neuroprotective Effects in a Kainic Acid-Induced Seizure Model in Rats.", "Abstract": {"AbstractText": ["Current anti-seizure drugs fail to control approximately 30% of epilepsies. Therefore, there is a need to develop more effective anti-seizure drugs, and medicinal plants provide an attractive source for new compounds. This study aimed to evaluate the possible anti-seizure and neuroprotective effects of neferine, an alkaloid from the lotus seed embryos of <i>Nelumbo nucifera</i>, in a kainic acid (KA)-induced seizure rat model and its underlying mechanisms. Rats were intraperitoneally (i.p.) administrated neferine (10 and 50 mg/kg) 30 min before KA injection (15 mg/kg, i.p.). Neferine pretreatment increased seizure latency and reduced seizure scores, prevented glutamate elevation and neuronal loss, and increased presynaptic protein synaptophysin and postsynaptic density protein 95 expression in the hippocampi of rats with KA. Neferine pretreatment also decreased glial cell activation and proinflammatory cytokine (interleukin-1\u03b2, interleukin-6, tumor necrosis factor-\u03b1) expression in the hippocampi of rats with KA. In addition, NOD-like receptor 3 (NLRP3) inflammasome, caspase-1, and interleukin-18 expression levels were decreased in the hippocampi of seizure rats pretreated with neferine. These results indicated that neferine reduced seizure severity, exerted neuroprotective effects, and ameliorated neuroinflammation in the hippocampi of KA-treated rats, possibly by inhibiting NLRP3 inflammasome activation and decreasing inflammatory cytokine secretion. Our findings highlight the potential of neferine as a therapeutic option in the treatment of epilepsy."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Anesthesiology, Far-Eastern Memorial Hospital, New Taipei City 22060, Taiwan."}, {"Identifier": [], "Affiliation": "Department of Mechanical Engineering, Yuan Ze University, Taoyuan 32003, Taiwan."}], "LastName": "Lin", "ForeName": "Tzu-Yu", "Initials": "TY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Medicine, Fu Jen Catholic University, New Taipei City 24205, Taiwan."}], "LastName": "Hung", "ForeName": "Chih-Yu", "Initials": "CY"}, {"Identifier": ["0000-0002-7597-7655"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cardiovascular Center, Division of Cardiovascular Surgery, Far-Eastern Memorial Hospital, New Taipei 22060, Taiwan."}, {"Identifier": [], "Affiliation": "Department of Electrical Engineering, Yuan Ze University, Taoyuan 32003, Taiwan."}], "LastName": "Chiu", "ForeName": "Kuan-Ming", "Initials": "KM"}, {"Identifier": ["0000-0001-7742-9508"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cardiovascular Center, Division of Cardiovascular Surgery, Far-Eastern Memorial Hospital, New Taipei 22060, Taiwan."}], "LastName": "Lee", "ForeName": "Ming-Yi", "Initials": "MY"}, {"Identifier": ["0000-0002-2217-3231"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Anesthesiology, Far-Eastern Memorial Hospital, New Taipei City 22060, Taiwan."}, {"Identifier": [], "Affiliation": "Department of Mechanical Engineering, Yuan Ze University, Taoyuan 32003, Taiwan."}], "LastName": "Lu", "ForeName": "Cheng-Wei", "Initials": "CW"}, {"Identifier": ["0000-0002-4675-0259"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Medicine, Fu Jen Catholic University, New Taipei City 24205, Taiwan."}, {"Identifier": [], "Affiliation": "Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 33303, Taiwan."}], "LastName": "Wang", "ForeName": "Su-Jane", "Initials": "SJ"}], "GrantList": [{"GrantID": "MOST 110-2320-B030-005", "Agency": "Ministry of Science and Technology, Taiwan", "Country": ""}, {"GrantID": "110-FEMH-FJU-01", "Agency": "Far Eastern Memorial Hospital, Taiwan", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Alkaloids"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Benzylisoquinolines"}, {"RegistryNumber": "0", "NameOfSubstance": "Cytokines"}, {"RegistryNumber": "0", "NameOfSubstance": "Inflammasomes"}, {"RegistryNumber": "0", "NameOfSubstance": "NLR Family, Pyrin Domain-Containing 3 Protein"}, {"RegistryNumber": "0", "NameOfSubstance": "Neuroprotective Agents"}, {"RegistryNumber": "2292-16-2", "NameOfSubstance": "neferine"}, {"RegistryNumber": "SIV03811UC", "NameOfSubstance": "Kainic Acid"}], "MeshHeadingList": [{"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Alkaloids"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Benzylisoquinolines"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cytokines"}, {"QualifierName": ["metabolism"], "DescriptorName": "Inflammasomes"}, {"QualifierName": ["adverse effects"], "DescriptorName": "Kainic Acid"}, {"QualifierName": ["metabolism"], "DescriptorName": "NLR Family, Pyrin Domain-Containing 3 Protein"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Neuroprotective Agents"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": ["metabolism"], "DescriptorName": "Seeds"}, {"QualifierName": ["chemically induced", "drug therapy"], "DescriptorName": "Seizures"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Singh A., Trevick S. The Epidemiology of Global Epilepsy. Neurol. Clin. 2016;34:837\u2013847. doi: 10.1016/j.ncl.2016.06.015.", "ArticleIdList": ["10.1016/j.ncl.2016.06.015", "27719996"]}, {"Citation": "L\u00f6scher W., Klitgaard H., Twyman R.E., Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat. Rev. Drug Discov. 2013;12:757\u2013776. doi: 10.1038/nrd4126.", "ArticleIdList": ["10.1038/nrd4126", "24052047"]}, {"Citation": "Perucca P., Gilliam F.G. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792\u2013802. doi: 10.1016/S1474-4422(12)70153-9.", "ArticleIdList": ["10.1016/S1474-4422(12)70153-9", "22832500"]}, {"Citation": "Tang F., Hartz A.M.S., Bauer B. Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers. Front. Neurol. 2017;8:301. doi: 10.3389/fneur.2017.00301.", "ArticleIdList": ["10.3389/fneur.2017.00301", "PMC5498483", "28729850"]}, {"Citation": "Auditeau E., Chassagne F., Bourdy G., Bounlu M., Jost J., Luna J., Ratsimbazafy V., Preux P.-M., Boumediene F. Herbal medicine for epilepsy seizures in Asia, Africa and Latin America: A systematic review. J. Ethnopharmacol. 2019;234:119\u2013153. doi: 10.1016/j.jep.2018.12.049.", "ArticleIdList": ["10.1016/j.jep.2018.12.049", "30610931"]}, {"Citation": "Sharifi-Rad J., Quispe C., Herrera-Bravo J., Martorell M., Sharopov F., Tumer T.B., Kurt B., Lankatillake C., Docea A.O., Moreira A.C., et al. A Pharmacological Perspective on Plant-derived Bioactive Molecules for Epilepsy. Neurochem. Res. 2021;46:2205\u20132225. doi: 10.1007/s11064-021-03376-0.", "ArticleIdList": ["10.1007/s11064-021-03376-0", "34120291"]}, {"Citation": "He L.-Y., Hu M.-B., Li R.-L., Zhao R., Fan L.-H., He L., Lu F., Ye X., Huang Y.-L., Wu C.-J. Natural Medicines for the Treatment of Epilepsy: Bioactive Components, Pharmacology and Mechanism. Front. Pharmacol. 2021;12:604040. doi: 10.3389/fphar.2021.604040.", "ArticleIdList": ["10.3389/fphar.2021.604040", "PMC7969896", "33746751"]}, {"Citation": "Lu C.-W., Huang Y.-C., Chiu K.-M., Lee M.-Y., Lin T.-Y., Wang S.-J. Enmein Decreases Synaptic Glutamate Release and Protects against Kainic Acid-Induced Brain Injury in Rats. Int. J. Mol. Sci. 2021;22:12966. doi: 10.3390/ijms222312966.", "ArticleIdList": ["10.3390/ijms222312966", "PMC8657722", "34884781"]}, {"Citation": "Lu C.-W., Lin T.-Y., Pan T.-L., Wang P.-W., Chiu K.-M., Lee M.-Y., Wang S.-J. Asiatic Acid Prevents Cognitive Deficits by Inhibiting Calpain Activation and Preserving Synaptic and Mitochondrial Function in Rats with Kainic Acid-Induced Seizure. Biomedicines. 2021;9:284. doi: 10.3390/biomedicines9030284.", "ArticleIdList": ["10.3390/biomedicines9030284", "PMC8001422", "33802221"]}, {"Citation": "Huang Y., Bai Y., Zhao L., Hu T., Hu B., Wang J., Xiang J. Pharmacokinetics and metabolism of neferine in rats after a single oral administration. Biopharm. Drug Dispos. 2007;28:361\u2013372. doi: 10.1002/bdd.556.", "ArticleIdList": ["10.1002/bdd.556", "17654697"]}, {"Citation": "Itoh A., Saitoh T., Tani K., Uchigaki M., Sugimoto Y., Yamada J., Nakajima H., Ohshiro H., Sun S., Tanahashi T. Bisbenzylisoquinoline Alkaloids from Nelumbo nucifera. Chem. Pharm. Bull. 2011;59:947\u2013951. doi: 10.1248/cpb.59.947.", "ArticleIdList": ["10.1248/cpb.59.947", "21804237"]}, {"Citation": "Pan Y., Cai B., Wang K., Wang S., Zhou S., Yu X., Xu B., Chen L. Neferine enhances insulin sensitivity in insulin resistant rats. J. Ethnopharmacol. 2009;124:98\u2013102. doi: 10.1016/j.jep.2009.04.008.", "ArticleIdList": ["10.1016/j.jep.2009.04.008", "19527823"]}, {"Citation": "Zhou Y.-J., Xiang J.-Z., Yuan H., Liu H., Tang Q., Hao H.-Z., Yin Z., Wang J., Ming Z. Neferine exerts its antithrombotic effect by inhibiting platelet aggregation and promoting dissociation of platelet aggregates. Thromb. Res. 2013;132:202\u2013210. doi: 10.1016/j.thromres.2013.05.018.", "ArticleIdList": ["10.1016/j.thromres.2013.05.018", "23773522"]}, {"Citation": "Asokan S.M., Mariappan R., Muthusamy S., Velmurugan B.K. Pharmacological benefits of neferine\u2014A comprehensive review. Life Sci. 2018;199:60\u201370. doi: 10.1016/j.lfs.2018.02.032.", "ArticleIdList": ["10.1016/j.lfs.2018.02.032", "29499283"]}, {"Citation": "Chiu K.-M., Hung Y.-L., Wang S.-J., Tsai Y.-J., Wu N.-L., Liang C.-W., Chang D.-C., Hung C.-F. Anti-Allergic and Anti-Inflammatory Effects of Neferine on RBL-2H3 Cells. Int. J. Mol. Sci. 2021;22:10994. doi: 10.3390/ijms222010994.", "ArticleIdList": ["10.3390/ijms222010994", "PMC8536162", "34681651"]}, {"Citation": "Priya L.B., Huang C., Hu R., Balasubramanian B., Baskaran R. An updated review on pharmacological properties of neferine\u2014A bisbenzylisoquinoline alkaloid from Nelumbo nucifera. J. Food Biochem. 2021;45:e13986. doi: 10.1111/jfbc.13986.", "ArticleIdList": ["10.1111/jfbc.13986", "34779018"]}, {"Citation": "Wang Y., Wang S., Wang R., Li S., Yuan Y. Neferine Exerts Antioxidant and Anti-Inflammatory Effects on Carbon Tetrachloride-Induced Liver Fibrosis by Inhibiting the MAPK and NF-\u03baB/I\u03baB\u03b1 Pathways. Evid.-Based Complement. Altern. Med. 2021;2021:4136019. doi: 10.1155/2021/4136019.", "ArticleIdList": ["10.1155/2021/4136019", "PMC7929649", "33680053"]}, {"Citation": "Wu C., Chen J., Yang R., Duan F., Li S., Chen X. Mitochondrial protective effect of neferine through the modulation of nuclear factor erythroid 2-related factor 2 signalling in ischaemic stroke. J. Cereb. Blood Flow Metab. 2019;176:400\u2013415. doi: 10.1111/bph.14537.", "ArticleIdList": ["10.1111/bph.14537", "PMC6329622", "30414381"]}, {"Citation": "Sengking J., Oka C., Wicha P., Yawoot N., Tocharus J., Chaichompoo W., Suksamrarn A., Tocharus C. Neferine Protects Against Brain Damage in Permanent Cerebral Ischemic Rat Associated with Autophagy Suppression and AMPK/mTOR Regulation. Mol. Neurobiol. 2021;58:6304\u20136315. doi: 10.1007/s12035-021-02554-z.", "ArticleIdList": ["10.1007/s12035-021-02554-z", "34498225"]}, {"Citation": "Jung H.A., Jin S.E., Choi R.J., Kim D.H., Kim Y.S., Ryu J.H., Son Y.K., Park J.J., Choi J.S. Anti-amnesic activity of neferine with antioxidant and anti-inflammatory capacities, as well as inhibition of ChEs and BACE1. Life Sci. 2010;87:420\u2013430. doi: 10.1016/j.lfs.2010.08.005.", "ArticleIdList": ["10.1016/j.lfs.2010.08.005", "20736023"]}, {"Citation": "Sugimoto Y., Furutani S., Nishimura K., Itoh A., Tanahashi T., Nakajima H., Oshiro H., Sun S., Yamada J. Antidepressant-like effects of neferine in the forced swimming test involve the serotonin1A (5-HT1A) receptor in mice. Eur. J. Pharmacol. 2010;634:62\u201367. doi: 10.1016/j.ejphar.2010.02.016.", "ArticleIdList": ["10.1016/j.ejphar.2010.02.016", "20176013"]}, {"Citation": "Yin S., Ran Q., Yang J., Zhao Y., Li C. Nootropic effect of neferine on aluminium chloride\u2013induced Alzheimer\u2019s disease in experimental models. J. Biochem. Mol. Toxicol. 2019;34:e22429. doi: 10.1002/jbt.22429.", "ArticleIdList": ["10.1002/jbt.22429", "31860774"]}, {"Citation": "Zhu J.-J., Yu B.-Y., Huang X.-K., He M.-Z., Chen B.-W., Chen T.-T., Fang H.-Y., Chen S.-Q., Fu X.-Q., Li P.-J., et al. Neferine Protects against Hypoxic-Ischemic Brain Damage in Neonatal Rats by Suppressing NLRP3-Mediated Inflammasome Activation. Oxidative Med. Cell. Longev. 2021;2021:6654954. doi: 10.1155/2021/6654954.", "ArticleIdList": ["10.1155/2021/6654954", "PMC8128543", "34046147"]}, {"Citation": "Upadhya D., Kodali M., Gitai D., Castro O.W., Zanirati G., Upadhya R., Attaluri S., Mitra E., Shuai B., Hattiangady B., et al. A Model of Chronic Temporal Lobe Epilepsy Presenting Constantly Rhythmic and Robust Spontaneous Seizures, Co-morbidities and Hippocampal Neuropathology. Aging Dis. 2019;10:915\u2013936. doi: 10.14336/AD.2019.0720.", "ArticleIdList": ["10.14336/AD.2019.0720", "PMC6764729", "31595192"]}, {"Citation": "Costa A.M., Lucchi C., Simonini C., Lustosa \u00cd.R., Biagini G. Status Epilepticus Dynamics Predicts Latency to Spontaneous Seizures in the Kainic Acid Model. Cell. Physiol. Biochem. 2020;54:493\u2013507. doi: 10.33594/000000232.", "ArticleIdList": ["10.33594/000000232", "32415763"]}, {"Citation": "Cristina de Brito Toscano E.C., Vieira \u00c9.L., Dias B.B.R., Caliari M.V., Gon\u00e7alves A.P., Giannetti A.V., Siqueira J.M., Suemoto C.K., Leite R.E.P., Nitrini R., et al. NLRP3 and NLRP1 inflammasomes are up-regulated in patients with mesial temporal lobe epilepsy and may contribute to overexpression of caspase-1 and IL-\u03b2 in sclerotic hippocampi. Brain Res. 2021;1752:147230. doi: 10.1016/j.brainres.2020.147230.", "ArticleIdList": ["10.1016/j.brainres.2020.147230", "33385378"]}, {"Citation": "Mohseni-Moghaddam P., Roghani M., Khaleghzadeh-Ahangar H., Sadr S.S., Sala C. A literature overview on epilepsy and inflammasome activation. Brain Res. Bull. 2021;172:229\u2013235. doi: 10.1016/j.brainresbull.2021.05.001.", "ArticleIdList": ["10.1016/j.brainresbull.2021.05.001", "33964347"]}, {"Citation": "Wang Q., Yu S., Simonyi A., Sun G.Y., Sun A.Y. Kainic Acid-Mediated Excitotoxicity as a Model for Neurodegeneration. Mol. Neurobiol. 2005;31:3\u201316. doi: 10.1385/MN:31:1-3:003.", "ArticleIdList": ["10.1385/MN:31:1-3:003", "15953808"]}, {"Citation": "Friedman L.K., Pellegrini-Giampietro D.E., Sperber E.F., Bennett M.V., Moshe S.L., Zukin R.S. Kainate-induced status epilepticus alters glutamate and GABAA receptor gene expression in adult rat hippocampus: An in situ hybridization study. J. Neurosci. 1994;14:2697\u20132707. doi: 10.1523/JNEUROSCI.14-05-02697.1994.", "ArticleIdList": ["10.1523/JNEUROSCI.14-05-02697.1994", "PMC6577484", "8182436"]}, {"Citation": "Spigolon G., Veronesi C., Bonny C., Vercelli A. c-Jun N-terminal kinase signaling pathway in excitotoxic cell death following kainic acid-induced status epilepticus. Eur. J. Neurosci. 2010;31:1261\u20131272. doi: 10.1111/j.1460-9568.2010.07158.x.", "ArticleIdList": ["10.1111/j.1460-9568.2010.07158.x", "20345908"]}, {"Citation": "Zhu X., Liu J., Huang S., Zhu W., Wang Y., Chen O., Xue J. Neuroprotective effects of isoliquiritigenin against cognitive impairment via suppression of synaptic dysfunction, neuronal injury, and neuroinflammation in rats with kainic acid-induced seizures. Int. Immunopharmacol. 2019;72:358\u2013366. doi: 10.1016/j.intimp.2019.04.028.", "ArticleIdList": ["10.1016/j.intimp.2019.04.028", "31030091"]}, {"Citation": "Zhang F.-X., Sun Q.-J., Zheng X.-Y., Lin Y.-T., Shang W., Wang A.-H., Duan R.-S., Chi Z.-F. Abnormal Expression of Synaptophysin, SNAP-25, and Synaptotagmin 1 in the Hippocampus of Kainic Acid-Exposed Rats with Behavioral Deficits. Cell. Mol. Neurobiol. 2014;34:813\u2013824. doi: 10.1007/s10571-014-0068-3.", "ArticleIdList": ["10.1007/s10571-014-0068-3", "24832394"]}, {"Citation": "Chapman A.G., Elwes R.D., Millan M.H., Polkey C.E., Meldrum B.S. Role of glutamate and aspartate in epileptogenesis; contribution of microdialysis studies in animal and man. Epilepsy Res. Suppl. 1996;12:239\u2013246.", "ArticleIdList": ["9302522"]}, {"Citation": "Vezzani A., Granata T. Brain Inflammation in Epilepsy: Experimental and Clinical Evidence. Epilepsia. 2005;46:1724\u20131743. doi: 10.1111/j.1528-1167.2005.00298.x.", "ArticleIdList": ["10.1111/j.1528-1167.2005.00298.x", "16302852"]}, {"Citation": "Kim D.H., Yoon B.H., Jung W.Y., Kim J.M., Park S.J., Park D.H., Huh Y., Park C., Cheong J.H., Lee K.-T., et al. Sinapic acid attenuates kainic acid-induced hippocampal neuronal damage in mice. Neuropharmacology. 2010;59:20\u201330. doi: 10.1016/j.neuropharm.2010.03.012.", "ArticleIdList": ["10.1016/j.neuropharm.2010.03.012", "20363233"]}, {"Citation": "Lu C.W., Hsieh H.L., Lin T.Y., Hsieh T.Y., Huang S.K., Wang S.J. Echinacoside, an Active Constituent of Cistanche Herba, Exerts a Neuroprotective Effect in a Kainic Acid Rat Model by Inhibiting Inflammatory Processes and Activating the Akt/GSK3\u03b2 Pathway. Biol. Pharm. Bull. 2018;41:1685\u20131693. doi: 10.1248/bpb.b18-00407.", "ArticleIdList": ["10.1248/bpb.b18-00407", "30197410"]}, {"Citation": "Liu Y., Wang S., Kan J., Zhang J., Zhou L., Huang Y., Zhang Y. Chinese Herbal Medicine Interventions in Neurological Disorder Therapeutics by Regulating Glutamate Signaling. Curr. Neuropharmacol. 2020;18:260\u2013276. doi: 10.2174/1570159X17666191101125530.", "ArticleIdList": ["10.2174/1570159X17666191101125530", "PMC7327939", "31686629"]}, {"Citation": "Rusina E., Bernard C., Williamson A. The Kainic Acid Models of Temporal Lobe Epilepsy. eNeuro. 2021;8:0337-20.2021. doi: 10.1523/ENEURO.0337-20.2021.", "ArticleIdList": ["10.1523/ENEURO.0337-20.2021", "PMC8174050", "33658312"]}, {"Citation": "Bahn S., Volk B., Wisden W. Kainate receptor gene expression in the developing rat brain. J. Neurosci. 1994;14:5525\u20135547. doi: 10.1523/JNEUROSCI.14-09-05525.1994.", "ArticleIdList": ["10.1523/JNEUROSCI.14-09-05525.1994", "PMC6577101", "8083752"]}, {"Citation": "Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: Mechanisms and relevance to human temporal lobe epilepsy. Neuroscience. 1985;14:375\u2013403. doi: 10.1016/0306-4522(85)90299-4.", "ArticleIdList": ["10.1016/0306-4522(85)90299-4", "2859548"]}, {"Citation": "Chittajallu R., Vignes M., Dev K.K., Barnes J.M., Collingridge G.L., Henley J.M. Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature. 1996;379:78\u201381. doi: 10.1038/379078a0.", "ArticleIdList": ["10.1038/379078a0", "8538745"]}, {"Citation": "Yeh K.C., Hung C.F., Lin Y.F., Chang D.C., Pai M.S., Wang S.J. Neferine, a bisbenzylisoquinoline alkaloid of Nelumbo nucifera, inhibits glutamate release in rat cerebrocortical nerve terminals through 5-HT1A receptors. Eur. J. Pharmacol. 2020;889:173589. doi: 10.1016/j.ejphar.2020.173589.", "ArticleIdList": ["10.1016/j.ejphar.2020.173589", "32961171"]}, {"Citation": "Murugesan A., Rani M.R.S., Hampson J., Zonjy B., Lacuey N., Faingold C.L., Friedman D., Devinsky O., Sainju R.K., Schuele S., et al. Serum serotonin levels in patients with epileptic seizures. Epilepsia. 2018;59:e91\u2013e97. doi: 10.1111/epi.14198.", "ArticleIdList": ["10.1111/epi.14198", "PMC6141199", "29771456"]}, {"Citation": "Akyuz E., Polat A.K., Eroglu E., Kullu I., Angelopoulou E., Paudel Y.N. Revisiting the role of neurotransmitters in epilepsy: An updated review. Life Sci. 2020;265:118826. doi: 10.1016/j.lfs.2020.118826.", "ArticleIdList": ["10.1016/j.lfs.2020.118826", "33259863"]}, {"Citation": "Penkowa M., Florit S., Giralt M., Quintana A., Molinero A., Carrasco J., Hidalgo J. Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures. J. Neurosci. Res. 2005;79:522\u2013534. doi: 10.1002/jnr.20387.", "ArticleIdList": ["10.1002/jnr.20387", "15614785"]}, {"Citation": "Vezzani A., Friedman A., Dingledine R. The role of inflammation in epileptogenesis. Neuropharmacology. 2013;69:16\u201324. doi: 10.1016/j.neuropharm.2012.04.004.", "ArticleIdList": ["10.1016/j.neuropharm.2012.04.004", "PMC3447120", "22521336"]}, {"Citation": "Swanson K.V., Deng M., Ting J.P.-Y. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 2019;19:477\u2013489. doi: 10.1038/s41577-019-0165-0.", "ArticleIdList": ["10.1038/s41577-019-0165-0", "PMC7807242", "31036962"]}, {"Citation": "Wu C., Zhang G., Chen L., Kim S., Yu J., Hu G., Chen J., Huang Y., Zheng G., Huang S. The Role of NLRP3 and IL-1\u03b2; in Refractory Epilepsy Brain Injury. Front. Neurol. 2020;10:1418. doi: 10.3389/fneur.2019.01418.", "ArticleIdList": ["10.3389/fneur.2019.01418", "PMC7025579", "32116990"]}, {"Citation": "Yue J., Wei Y.J., Yang X., Liu S., Yang H., Zhang C. NLRP3 inflammasome and endoplasmic reticulum stress in the epileptogenic zone in temporal lobe epilepsy: Molecular insights into their interdependence. Neuropathol. Appl. Neurobiol. 2020;46:770\u2013785. doi: 10.1111/nan.12621.", "ArticleIdList": ["10.1111/nan.12621", "32311777"]}, {"Citation": "Schroder K., Tschopp J. The Inflammasomes. Cell. 2010;140:821\u2013832. doi: 10.1016/j.cell.2010.01.040.", "ArticleIdList": ["10.1016/j.cell.2010.01.040", "20303873"]}, {"Citation": "Shao B.-Z., Xu Z.-Q., Han B.-Z., Su D.-F., Liu C. NLRP3 inflammasome and its inhibitors: A review. Front. Pharmacol. 2015;6:262. doi: 10.3389/fphar.2015.00262.", "ArticleIdList": ["10.3389/fphar.2015.00262", "PMC4633676", "26594174"]}, {"Citation": "Meng X.-F., Tan L., Tan M.-S., Jiang T., Tan C.-C., Li M.-M., Wang H.-F., Yu J.-T. Inhibition of the NLRP3 inflammasome provides neuroprotection in rats following amygdala kindling-induced status epilepticus. J. Neuroinflamm. 2014;11:212. doi: 10.1186/s12974-014-0212-5.", "ArticleIdList": ["10.1186/s12974-014-0212-5", "PMC4275944", "25516224"]}, {"Citation": "Rong S., Wan D., Fan Y., Liu S., Sun K., Huo J., Zhang P., Li X., Xie X., Wang F., et al. Amentoflavone Affects Epileptogenesis and Exerts Neuroprotective Effects by Inhibiting NLRP3 Inflammasome. Front. Pharmacol. 2019;10:856. doi: 10.3389/fphar.2019.00856.", "ArticleIdList": ["10.3389/fphar.2019.00856", "PMC6682693", "31417409"]}, {"Citation": "Lu C.-W., Lin T.-Y., Chiu K.-M., Lee M.-Y., Huang J.-H., Wang S.-J. Silymarin Inhibits Glutamate Release and Prevents against Kainic Acid-Induced Excitotoxic Injury in Rats. Biomedicines. 2020;8:486. doi: 10.3390/biomedicines8110486.", "ArticleIdList": ["10.3390/biomedicines8110486", "PMC7695262", "33182349"]}, {"Citation": "Racine R.J. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972;32:281\u2013294. doi: 10.1016/0013-4694(72)90177-0.", "ArticleIdList": ["10.1016/0013-4694(72)90177-0", "4110397"]}, {"Citation": "Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs. Front. Psychol. 2013;4:863. doi: 10.3389/fpsyg.2013.00863.", "ArticleIdList": ["10.3389/fpsyg.2013.00863", "PMC3840331", "24324449"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "2", "Day": "25"}, {"Year": "2022", "Month": "4", "Day": "1"}, {"Year": "2022", "Month": "4", "Day": "7"}, {"Year": "2022", "Month": "4", "Day": "23", "Hour": "1", "Minute": "10"}, {"Year": "2022", "Month": "4", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "4", "Day": "8"}], "PublicationStatus": "epublish", "ArticleIdList": ["35456948", "PMC9027762", "10.3390/ijms23084130", "ijms23084130"]}}], "PubmedBookArticle": []}